Navigation Links
Lilly and Incyte Announce Collaboration for Development and Commercialization of Oral Anti-Inflammatory and Autoimmune Therapies
Date:12/21/2009

INDIANAPOLIS and WILMINGTON, Del., Dec. 21 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (Nasdaq: INCY) announced today that they have entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of Incyte's oral JAK1/JAK2 inhibitor, INCB28050, and certain follow on compounds, for inflammatory and autoimmune diseases. The lead compound, INCB28050, is currently being studied in a six-month dose-ranging Phase II trial for rheumatoid arthritis.

Under the terms of the agreement, Lilly will receive worldwide rights to develop and commercialize INCB28050 as an oral treatment for all inflammatory conditions. In exchange for these rights, Incyte will receive an initial payment of $90 million and is eligible for up to $665 million in additional potential development, regulatory, and commercialization milestones, as well as tiered, double-digit royalty payments on future global sales with rates ranging up to twenty percent if a product is successfully commercialized.

"This new alliance with Incyte reinforces Lilly's commitment to expand our presence in inflammation and autoimmunity through the development of a new class of oral anti-inflammatory therapies," said Eiry Roberts, M.D. Lilly vice president for autoimmune product development. "We look forward to continuing the development of INCB28050 in RA and initiating additional clinical studies to help address the unmet patient needs from debilitating autoimmune and inflammatory diseases."

Paul Friedman, Incyte's president and chief executive officer, stated, "Lilly's success in bringing novel therapies to market, their commitment to building a franchise in inflammation and
'/>"/>

SOURCE Eli Lilly and Company; Incyte Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... -- Levi & Korsinsky is investigating the Board of ... BIIB) for possible violations of federal securities laws. The ... and/or directors have violated Sections 10(b) and 20(a) of ... 24, 2015, prior to the opening of the market, ... other things, the Company lowered its prior revenue guidance ...
(Date:8/4/2015)... Inc. (Nasdaq: ISIS ) today reported net income ... and six months ended June 30, 2015, respectively, compared ... million for the same periods in 2014. Isis, significantly ... than $90 million of revenue Isis earned in the ... to license  ISIS-FXI Rx .  Isis increased its cash ...
(Date:8/4/2015)... FLORHAM PARK, N.J. , Aug. 4, ... partnered with University of Massachusetts Medical School,s ... enhancements and support regarding clinical protocols and ... Workflow Platform. Specialty medication ... ArmadaOne and helps to ensure optimal patient ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation of Biogen Inc. and Its Board of Directors in Connection with Possible Violations of Federal Securities Laws -- BIIB 2Isis Reports Financial Results And Highlights For Second Quarter 2015 2Isis Reports Financial Results And Highlights For Second Quarter 2015 3Isis Reports Financial Results And Highlights For Second Quarter 2015 4Isis Reports Financial Results And Highlights For Second Quarter 2015 5Isis Reports Financial Results And Highlights For Second Quarter 2015 6Isis Reports Financial Results And Highlights For Second Quarter 2015 7Isis Reports Financial Results And Highlights For Second Quarter 2015 8Isis Reports Financial Results And Highlights For Second Quarter 2015 9Isis Reports Financial Results And Highlights For Second Quarter 2015 10Isis Reports Financial Results And Highlights For Second Quarter 2015 11Isis Reports Financial Results And Highlights For Second Quarter 2015 12Isis Reports Financial Results And Highlights For Second Quarter 2015 13Isis Reports Financial Results And Highlights For Second Quarter 2015 14Isis Reports Financial Results And Highlights For Second Quarter 2015 15Isis Reports Financial Results And Highlights For Second Quarter 2015 16Armada Health Care collaborates with University of Massachusetts Medical School for ArmadaOne Specialty Pharmacy Platform 2Armada Health Care collaborates with University of Massachusetts Medical School for ArmadaOne Specialty Pharmacy Platform 3
... SILVER SPRING, Md. , May 26 The U.S. Food and ... of severe liver injury in patients taking the weight-loss medication orlistat, marketed as ... , (Logo:   ... The FDA has ...
... May 26 CANTEL MEDICAL CORP. (NYSE: ... CEO, will be presenting at the Jefferies 2010 Global Life Sciences Conference. ... Wednesday, June 9, 2010 at The Grand Hyatt Hotel in ... following the presentation. In addition, Mr. Krakauer and Seth R. Segel ...
Cached Medicine Technology:FDA: Rare Cases of Liver Injury Reported With Use of Xenical, Alli 2FDA: Rare Cases of Liver Injury Reported With Use of Xenical, Alli 3Cantel Medical Corp. to Present at the Jefferies 2010 Global Life Sciences Conference 2
(Date:8/4/2015)... ... , ... Rhode Island Medical Imaging (RIMI) is pleased to announce the opening ... Robin Road in Lincoln, RI. This satellite office will provide x-ray and ultrasound ... x-ray hours in the state, which includes evenings and weekends. , “This satellite ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... An ... found financial incentives to be a viable method for encouraging people to lose weight. ... on the future of their weight loss success, adding a financial incentive to the ...
(Date:8/4/2015)... ... August 04, 2015 , ... Angelina Jolie is in ... millions of women every year. Dr. Angela DeRosa, DO, MBA, CPE aka ... therapies, takes the scary unknown out of menopause. , Myth #1: Menopause only ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... the industry. , Worldwide Power Products is expanding its reach in Texas. Effective ... the Alpine Power Systems North Texas generator division. With the North Texas ...
(Date:8/4/2015)... ... 04, 2015 , ... Recent studies in the ... in binge drinking among certain populations and specific locations. Researchers, who ... examine trends and evidence to help facilitate health care treatment to meet current ...
Breaking Medicine News(10 mins):Health News:Rhode Island Medical Imaging Opens Satellite Imaging Center on Wake Robin Road in Lincoln 2Health News:Article on Incentivizing Weight Loss Mirrors Similar Motivations Surrounding Weight Loss Surgery, Says Dr. Feiz & Associates 2Health News:"Dr. Hot Flash" Debunks the Top 5 Menopause Myths 2Health News:"Dr. Hot Flash" Debunks the Top 5 Menopause Myths 3Health News:North Texas Acquisition Press Release 2Health News:DARA Responds To International Trends in Binge Drinking 2Health News:DARA Responds To International Trends in Binge Drinking 3
... 40 million Needy Children and Adults to be Affected Nationwide, Study ... ... A survey released today,by Spectrum Science Communications states that a little known,anti-privatization ... administer its Medicaid program. The,measure, offered as an amendment to the House-passed ...
... afflicted humans, primate ancestors , , FRIDAY, Feb. 29 (HealthDay News) ... as protection against a group of viruses that includes HIV ... that their finding suggests the current AIDS epidemic is not ... in Asian macaques is a hybrid of two existing proteins, ...
... Openings to Feature Cincinnati Reds Great, Doug Flynn, and Pitching ... ... RICHEY, Fla., Feb 29 Zounds,Hearing, a unique manufacturing and retail ... professional,service, opened its doors recently in the Westfield Sarasota Square Mall,(Sarasota) ...
... of Health Professionals Finds Acute Shortage of ... MILPITAS, Calif., Feb. 29 With mounting evidence that,many ... the,nation,s growing epidemic of diabetes, the Johnson & Johnson ... the U.S. to,improve how practitioners deliver diabetes care in ...
... lung cancer, according to a study of more than ... increase the risk of developing it. , Our study ... did not show any evidence for a decreased risk ... Slatore, M.D., of the University of Washington, in Seattle. ...
... diseases like chronic bronchitis, but genes also play a ... Sweden, who studied more than 40,000 Swedish twins to ... each play a role ion the development of chronic ... genetic component and smoking is a primary risk factor ...
Cached Medicine News:Health News:Farm Bill Provision Will Disrupt Arkansas Medicaid Program 2Health News:Farm Bill Provision Will Disrupt Arkansas Medicaid Program 3Health News:Monkey Gene That Blocks AIDS Viruses Evolved More Than Once 2Health News:Zounds! - Sarasota and Port Richey 'Hear' New Retail Concept Coming 2Health News:Zounds! - Sarasota and Port Richey 'Hear' New Retail Concept Coming 3Health News:Johnson & Johnson Diabetes Institute, LLC Launches New Center to Provide State-of-the-Art Education, Training to Health Professionals 2Health News:Johnson & Johnson Diabetes Institute, LLC Launches New Center to Provide State-of-the-Art Education, Training to Health Professionals 3Health News:Johnson & Johnson Diabetes Institute, LLC Launches New Center to Provide State-of-the-Art Education, Training to Health Professionals 4Health News:Johnson & Johnson Diabetes Institute, LLC Launches New Center to Provide State-of-the-Art Education, Training to Health Professionals 5Health News:Certain vitamin supplements may increase lung cancer risk, especially in smokers 2Health News:Genetic factors in smoking also increase risk of chronic bronchitis 2
... The CELL-DYN 3200 sets a benchmark ... light scatter for WBC, RBC, PLT ... meets the needs of today's laboratory. ... five-part differential analysis, automated sample handling, ...
... Test is a color immunochromatographic assay using ... labeled color particles coated at two separate ... greater sensitivity than the conventional single label ... procedure, a throat swab is subjected to ...
... Fertell test is an easy to use, one ... reserve by means of determining the amount of ... sample. The test is performed two days after ... menstrual cycle) and is similar in design and ...
... The Cholestech GDX System delivers an unmatched ... the ideal solution for assessing and monitoring a ... product demo, click here ., ,The CLIA-waived ... delivers A1C results in less than 5 minutes. ...
Medicine Products: